Эволюция антагонистов минералокортикоидных рецепторов: эплеренон и спиронолактон
- Авторы: Леонова М.В.1, Алимова Э.Э.1, Еремина Ю.Н.1
-
Учреждения:
- ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России
- Выпуск: Том 19, № 10 (2017)
- Страницы: 60-65
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/94895
- DOI: https://doi.org/10.26442/2075-1753_19.10.60-65
- ID: 94895
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Марина Васильевна Леонова
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России
Email: anti23@mail.ru
д-р мед. наук, проф., зав. каф. клин. фармакологии лечебного фак-та 117997, Россия, Москва, ул. Островитянова, д. 1
Эльмира Эрфановна Алимова
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава Россииканд. мед. наук, доц. каф. клин. фармакологии лечебного фак-та 117997, Россия, Москва, ул. Островитянова, д. 1
Юлия Николаевна Еремина
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава Россииканд. мед. наук, доц. каф. клин. фармакологии лечебного фак-та 117997, Россия, Москва, ул. Островитянова, д. 1
Список литературы
- Garthwaite S.M, McMahon E.G. The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004;217:27-31.
- Mihailidou A.S, Funder J.W. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005; 70 (5-7): 347-51.
- Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Reviews 2005; 10: 23-9.
- Pitt B, Gheorghiade M, Zannad F. et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejections fraction №30%, Eur J Heart Fail 2006;8:295-301.
- Seferovic P.M, Pelliccia F, Zivkovic I et al. Review mineralocorticoid receptor antagonists, a class beyond spironolactone - focus on the special pharmacologic properties of eplerenone. Int J Cardiol 2015; 200: 3-7.
- Williams B, MacDonald T.M, Morant S et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-68.
- 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-219.
- Weinberger M.H, Roniker B, Krause S.L, Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-16.
- White W.B, Carr A.A, Krause S. et al. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003; 92: 38-42.
- Williams G.H, Burgess E, Kolloch R.E et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93 (8): 990-6.
- White W.B, Duprez D, St Hillaire R. et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003;41:1021-6.
- Flack J.M, Oparil S, Pratt J.H. et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148-55.
- Pelliccia F, Patti G, Rosano G. et al. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol 2014; 177 (1): 219-28.
- Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 2003; 18: 1984-92.
- Pitt B, Reichek N, Willenbrock R. et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-8.
- Epstein M, Williams G.H, Weinberger M et al. Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol 2006; 1:940-51.
- Pitt B, Zannad F, Remme W.J et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
- Chen Y, Wang H, Lu Y. et al. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Medicine 2015;13:10.
- Bapoje S.R, Bahia A, Hokanson J.E et al. The Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients with Left Ventricular Systolic Dysfunction: A Meta-analysis of Randomized Controlled Trials. Circ Heart Fail 2013; 2.
- 2016 E.S.C Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016.
- Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-21.
- Zannad F, McMurray J.J.V, Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364 (1): 11-21.
- Danjuma M.I, Mukherjee I, Makaronidis J, Osula S. Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles. Curr Hypertens Rep 2014; 16: 414.
- Burgess E, Lacourciere Y, Ruilope L.M et al. Assessment of the long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003; 25: 2388-404.
Дополнительные файлы
